Dirigirse al eje TRIB3-MYC en el cáncer: conocimientos mecanicistas y estrategias de disrupción terapéutica
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.La pseudokinasa 3 de Tribbles (TRIB3) es un nuevo objetivo que se une a MYC, un factor clave del cáncer. La inhibición de TRIB3 reduce efectivamente los niveles de MYC, suprimiendo el crecimiento tumoral en varios tipos de cáncer y ofreciendo nuevas vías terapéuticas.
Área De La Ciencia
- En el campo de la oncología
- Biología molecular
- Descubrimiento de drogas
Sus Antecedentes
- El factor de transcripción oncogénico MYC promueve la proliferación del cáncer y la resistencia al tratamiento.
- La gran interfaz de MYC ha obstaculizado el desarrollo directo de medicamentos.
- Se identificó a la pseudokinasa 3 de Tribbles (TRIB3) como un andamio de unión a MYC, que influye en la estabilidad y actividad de MYC.
Objetivo Del Estudio
- Revisar los datos estructurales, bioquímicos y in vivo sobre la interacción con el TRIB3-MYC.
- Explorar estrategias terapéuticas dirigidas al eje TRIB3-MYC.
- Discutir los desafíos traslacionales y las direcciones futuras para las terapias dirigidas a MYC.
Principales Métodos
- Integración de los datos estructurales y bioquímicos sobre la unión TRIB3-MYC.
- Análisis de estudios in vivo que demuestran la supresión del tumor tras la modulación de TRIB3.
- Revisión de las modalidades terapéuticas emergentes, incluidos los péptidos, las moléculas pequeñas y los PROTAC.
Principales Resultados
- La unión de TRIB3 estabiliza el MYC; el desalojo o inhibición de TRIB3 reduce los niveles de MYC y silencia su programa oncogénico.
- Se detallaron dos circuitos tumorales sólidos distintos que involucran a TRIB3: el adenocarcinoma pulmonar y el carcinoma de mama.
- Las terapias combinadas que involucran disruptores TRIB3 muestran efectos sinérgicos en modelos preclínicos.
Conclusiones
- La interfaz TRIB3-MYC representa un objetivo para el bloqueo directo de MYC.
- Las terapias emergentes dirigidas a TRIB3 ofrecen estrategias prometedoras para los cánceres impulsados por MYC.
- Los avances en la administración de medicamentos, la selección de pacientes y las vías regulatorias facilitan la traducción clínica.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.